Methods and Antibody Compositions for Tumor Treatment
1 Assignment
0 Petitions
Accused Products
Abstract
The present invention provides bispecific antibodies that bind to CD3 and tumor antigens and methods of using the same. According to certain embodiments, the bispecific antibodies of the invention exhibit reduced effector functions and have a unique binding profile with regard to Fcγ receptors. The bispecific antibodies are engineered to efficiently induce T cell-mediated killing of tumor cells. According to certain embodiments, the present invention provides bispecific antigen-binding molecules comprising a first antigen-binding domain that specifically binds human CD3, a second antigen-binding molecule that specifically binds human CD20, and an Fc domain that binds Fcγ receptors with a specific binding pattern. In certain embodiments, the bispecific antigen-binding molecules of the present invention are capable of inhibiting the growth of B-cell or melanoma tumors expressing CD20. The bispecific antibodies of the invention are useful for the treatment of various cancers as well as other CD20-related diseases and disorders.
-
Citations
100 Claims
-
1-4. -4. (canceled)
- 5. A method for treating a B-cell cancer in a subject, the method comprising administering to the subject a therapeutic amount of a bispecific antibody comprising a first antigen-binding domain that binds human CD3, a second antigen-binding domain that binds human CD20, and a chimeric Fc domain tethered to each of the first and second antigen-binding domains.
-
6-17. -17. (canceled)
-
26-34. -34. (canceled)
-
35. A method of treating CD20-expressing melanoma cancer in a subject, the method comprising administering a therapeutic amount of a bispecific antibody comprising a first antigen-binding domain that binds human CD3, a second antigen-binding domain that binds human CD20, and a chimeric Fc domain tethered to each of the first and second antigen-binding domains, wherein the amount is sufficient to reduce tumor burden, inhibit tumor growth or reduce tumor development in the subject.
-
37-44. -44. (canceled)
-
47-50. -50. (canceled)
-
52. (canceled)
-
54. (canceled)
-
66. (canceled)
-
83-86. -86. (canceled)
-
89-91. -91. (canceled)
-
93. (canceled)
-
95. (canceled)
-
99. A bispecific antibody comprising a first antigen-binding domain that binds human CD3, a second antigen-binding domain that binds human CD20, and a chimeric Fc domain tethered to each of the first and second antigen-binding domains.
-
100-164. -164. (canceled)
Specification